Skip to content

Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E

Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04509609
Acronym
NeuroLGMD2E
Enrollment
33
Registered
2020-08-12
Start date
2020-06-01
Completion date
2021-09-30
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LGMD2E

Brief summary

A retrospective observational study that will enable us to collect retrospective data from the clinical records of LGMD 2E patients in order to highlight any possible correlation between: * clinical variables and patient age, * clinical variables and other clinical variables, * clinical variables and clinical outcomes. The study will help to define the natural history of this rare disease and to ameliorate the management of these patients.

Detailed description

Retrospective observational study. Retrospective data from clinical charts of patients affected by LGMD 2E will be collected after the subscription of informed consent.Data considered will include any clinical variable measured, both objective and subjective. All data obtained will be anonimized before any treatment. Data will be grouped according to the age of the patient, in order to have more data for each age and to gain a trustable description of the disease progression. The possible correlation of each variable to age, to other variables and to objective clinical outcomes will be studied. Clinical outcomes considered will include age of loss of deambulation, age of introduction of respiratory assist, age of introduction of cardiological therapy. Data collected will also be divided in two groups according to different genetic diagnosis in order to evaluate phenotipical differences of genotypical clesses. First group will count all patient with the truncating mutation c.377\_384duplCAGTAGGA in exon 3, both in heterozigosis and in homozigosis Second group will include all the other patients. Both on the global data collection and on data divided according to genotype, statistical analysis will be performed. Those analysis will study linear regression both with the univariate, bivariate and multivariate model.

Interventions

OTHERExon 3 truncating mutation

Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis

OTHERAny other mutation in SGBC gene

Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis

Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Gene based diagnosis of LGMD 2E * Subscription of informed consent when applicable

Exclusion criteria

* Lacking gene based diagnosis of LGMD 2E * Lacking subscription of informed consent when applicable

Design outcomes

Primary

MeasureTime frameDescription
Natural historydecember 2020The clinical progression of the disease will be studied considering for each clinical variable its evolution according to patients' ages. This both in overall cohort and in genetic subgroups.

Secondary

MeasureTime frameDescription
Guidelinesdecember 2020The collection of clinical variables describing the progression of the disease will enable a better clinical management of these patients

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026